The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine ...

Background Cancer, a major global health challenge, not only threatens lives but also imposes severe financial burdens, known as ‘financial toxicity’. This strain extends beyond treatment costs to ...

Diane Simeone, MD, credits her fascination with human biology and dedication as a student athlete with instilling in her a ...

A new nationwide study shows that cancer patients who regularly participate in digital cancer symptom reporting through electronic monitoring systems experience significantly improved outcomes and ...

The BC Cancer Foundation is launching a fundraising campaign to support the next three years of immunotherapy research at BC ...

CANCER patients can now have access to world-class oncology treatment with the soft opening of the Singapore Cancer Center ...

William Dale, MD, PhD, FASCO, highlighted the shift from the first geriatric oncology guidelines made in 2018 to the ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Researchers at The Wistar Institute, led by Jessie Villanueva, Ph.D., have made significant strides in combating ...

Paul Nghiem, MD, PhD, and the Nghiem Lab have championed innovations in MCC treatment, delivering new treatment options, ...

Clayton Irvine, PharmD, MBA, MS, senior manager of oncology care at Mayo Clinic, emphasizes the need for health care ...

As part of The Wistar Institute's Melanoma Research Center, the Villanueva lab pursues new ways to overcome the challenge of melanoma drug resistance. In this paper, the group took aim at melanomas ...